Esperion Therapeutics Net Income
| ESPR Stock | USD 3.39 0.16 4.51% |
As of the 31st of January, Esperion Therapeutics shows the Mean Deviation of 3.72, coefficient of variation of 960.3, and Downside Deviation of 4.67. Esperion Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Esperion Therapeutics standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Esperion Therapeutics is priced favorably, providing market reflects its regular price of 3.39 per share. Given that Esperion Therapeutics has jensen alpha of 0.4124, we urge you to verify Esperion Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.
Esperion Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.4758 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -46.6 M | -48.9 M | |
| Net Loss | -46.6 M | -48.9 M | |
| Net Loss | -210.3 M | -220.8 M | |
| Net Loss | (0.25) | (0.26) | |
| Net Income Per E B T | 0.79 | 0.70 |
Esperion | Net Income | Build AI portfolio with Esperion Stock |
Evaluating Esperion Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Esperion Therapeutics's fundamental strength.
Latest Esperion Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Esperion Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Esperion Therapeutics financial statement analysis. It represents the amount of money remaining after all of Esperion Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Esperion Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Esperion Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (51.74 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Esperion Net Income Regression Statistics
| Arithmetic Mean | (99,364,583) | |
| Coefficient Of Variation | (86.91) | |
| Mean Deviation | 73,903,118 | |
| Median | (51,745,000) | |
| Standard Deviation | 86,358,339 | |
| Sample Variance | 7457.8T | |
| Range | 258.4M | |
| R-Value | (0.46) | |
| Mean Square Error | 6254.1T | |
| R-Squared | 0.21 | |
| Significance | 0.06 | |
| Slope | (7,907,727) | |
| Total Sum of Squares | 119324.2T |
Esperion Net Income History
Other Fundumenentals of Esperion Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Esperion Therapeutics Net Income component correlations
Esperion Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Esperion Therapeutics is extremely important. It helps to project a fair market value of Esperion Stock properly, considering its historical fundamentals such as Net Income. Since Esperion Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Esperion Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Esperion Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Esperion have expansion opportunities? Factors like these will boost the valuation of Esperion Therapeutics. Projected growth potential of Esperion fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Esperion Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.54) | Revenue Per Share | Quarterly Revenue Growth 0.691 | Return On Assets | Return On Equity |
The market value of Esperion Therapeutics is measured differently than its book value, which is the value of Esperion that is recorded on the company's balance sheet. Investors also form their own opinion of Esperion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Esperion Therapeutics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Esperion Therapeutics' market value can be influenced by many factors that don't directly affect Esperion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Esperion Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Esperion Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Esperion Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Esperion Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Esperion Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Esperion Therapeutics.
| 11/02/2025 |
| 01/31/2026 |
If you would invest 0.00 in Esperion Therapeutics on November 2, 2025 and sell it all today you would earn a total of 0.00 from holding Esperion Therapeutics or generate 0.0% return on investment in Esperion Therapeutics over 90 days. Esperion Therapeutics is related to or competes with SNDL, SIGA Technologies, Aquestive Therapeutics, Emergent Biosolutions, Ventyx Biosciences, Corvus Pharmaceuticals, and Olema Pharmaceuticals. Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patien... More
Esperion Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Esperion Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Esperion Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.67 | |||
| Information Ratio | 0.0914 | |||
| Maximum Drawdown | 24.91 | |||
| Value At Risk | (7.04) | |||
| Potential Upside | 7.05 |
Esperion Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Esperion Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Esperion Therapeutics' standard deviation. In reality, there are many statistical measures that can use Esperion Therapeutics historical prices to predict the future Esperion Therapeutics' volatility.| Risk Adjusted Performance | 0.0841 | |||
| Jensen Alpha | 0.4124 | |||
| Total Risk Alpha | 0.1514 | |||
| Sortino Ratio | 0.0944 | |||
| Treynor Ratio | 0.3165 |
Esperion Therapeutics January 31, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0841 | |||
| Market Risk Adjusted Performance | 0.3265 | |||
| Mean Deviation | 3.72 | |||
| Semi Deviation | 4.25 | |||
| Downside Deviation | 4.67 | |||
| Coefficient Of Variation | 960.3 | |||
| Standard Deviation | 4.82 | |||
| Variance | 23.26 | |||
| Information Ratio | 0.0914 | |||
| Jensen Alpha | 0.4124 | |||
| Total Risk Alpha | 0.1514 | |||
| Sortino Ratio | 0.0944 | |||
| Treynor Ratio | 0.3165 | |||
| Maximum Drawdown | 24.91 | |||
| Value At Risk | (7.04) | |||
| Potential Upside | 7.05 | |||
| Downside Variance | 21.79 | |||
| Semi Variance | 18.08 | |||
| Expected Short fall | (3.98) | |||
| Skewness | 0.0273 | |||
| Kurtosis | 1.8 |
Esperion Therapeutics Backtested Returns
Esperion Therapeutics appears to be unstable, given 3 months investment horizon. Esperion Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0708, which denotes the company had a 0.0708 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Esperion Therapeutics, which you can use to evaluate the volatility of the firm. Please utilize Esperion Therapeutics' Downside Deviation of 4.67, mean deviation of 3.72, and Coefficient Of Variation of 960.3 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Esperion Therapeutics holds a performance score of 5. The firm shows a Beta (market volatility) of 1.56, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Esperion Therapeutics will likely underperform. Please check Esperion Therapeutics' value at risk, as well as the relationship between the kurtosis and price action indicator , to make a quick decision on whether Esperion Therapeutics' price patterns will revert.
Auto-correlation | -0.82 |
Excellent reverse predictability
Esperion Therapeutics has excellent reverse predictability. Overlapping area represents the amount of predictability between Esperion Therapeutics time series from 2nd of November 2025 to 17th of December 2025 and 17th of December 2025 to 31st of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Esperion Therapeutics price movement. The serial correlation of -0.82 indicates that around 82.0% of current Esperion Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.82 | |
| Spearman Rank Test | -0.62 | |
| Residual Average | 0.0 | |
| Price Variance | 0.11 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Esperion Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Esperion Therapeutics reported net income of (51.74 Million). This is 115.16% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 109.06% higher than that of the company.
Esperion Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Esperion Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Esperion Therapeutics could also be used in its relative valuation, which is a method of valuing Esperion Therapeutics by comparing valuation metrics of similar companies.Esperion Therapeutics is currently under evaluation in net income category among its peers.
Esperion Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Esperion Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Esperion Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Esperion Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Esperion Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Esperion Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Esperion Therapeutics' value.| Shares | Two Sigma Investments Llc | 2025-06-30 | 1.8 M | Northern Trust Corp | 2025-06-30 | 1.8 M | Ubs Group Ag | 2025-06-30 | 1.5 M | Woodline Partners Lp | 2025-06-30 | 1.5 M | Royal Bank Of Canada | 2025-06-30 | 1.2 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.1 M | Susquehanna International Group, Llp | 2025-06-30 | 836.5 K | Bank Of America Corp | 2025-06-30 | 836.3 K | Goldman Sachs Group Inc | 2025-06-30 | 798.8 K | Blackrock Inc | 2025-06-30 | 14.7 M | Vanguard Group Inc | 2025-06-30 | 11.7 M |
Esperion Fundamentals
| Return On Equity | -2.61 | ||||
| Return On Asset | -0.0542 | ||||
| Profit Margin | (0.35) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 1.06 B | ||||
| Shares Outstanding | 237.07 M | ||||
| Shares Owned By Insiders | 0.61 % | ||||
| Shares Owned By Institutions | 48.17 % | ||||
| Number Of Shares Shorted | 37.44 M | ||||
| Price To Earning | (8.19) X | ||||
| Price To Book | 98.42 X | ||||
| Price To Sales | 2.78 X | ||||
| Revenue | 332.31 M | ||||
| Gross Profit | 131.9 M | ||||
| EBITDA | 7.57 M | ||||
| Net Income | (51.74 M) | ||||
| Cash And Equivalents | 185.84 M | ||||
| Cash Per Share | 2.79 X | ||||
| Total Debt | 591.21 M | ||||
| Current Ratio | 3.07 X | ||||
| Book Value Per Share | (2.20) X | ||||
| Cash Flow From Operations | (23.65 M) | ||||
| Short Ratio | 6.69 X | ||||
| Earnings Per Share | (0.54) X | ||||
| Price To Earnings To Growth | (4.78) X | ||||
| Target Price | 6.5 | ||||
| Number Of Employees | 304 | ||||
| Beta | 1.04 | ||||
| Market Capitalization | 843.61 M | ||||
| Total Asset | 343.82 M | ||||
| Retained Earnings | (1.6 B) | ||||
| Working Capital | 91.77 M | ||||
| Current Asset | 214.39 M | ||||
| Current Liabilities | 5.62 M | ||||
| Net Asset | 343.82 M |
About Esperion Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Esperion Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Esperion Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Esperion Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Esperion Stock
| 0.8 | ACLX | Arcellx | PairCorr |
| 0.63 | APLT | Applied Therapeutics | PairCorr |
| 0.61 | EVGN | Evogene | PairCorr |
| 0.6 | RANI | Rani Therapeutics | PairCorr |
| 0.58 | RNAZ | Transcode Therapeutics | PairCorr |
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.